Dr. Reddy's Laboratories reported second-quarter FY2027 revenue of ₹86.71 billion, down approximately 1.5% year over year, and profit attributable to equity shareholders of ₹9.25 billion.
North American revenue declined approximately 23% to ₹24.89 billion, reflecting pricing pressure and lower sales of existing products, particularly lenalidomide.
The company's disclosures also describe semaglutide API batches that were found out of specification, related inventory provisions, and expected returns associated with a Canadian product recall.
Separately, its October 23 investor presentation reported multiple FDA inspection observations at manufacturing facilities, with responses submitted or planned according to the respective timelines. These inspection observations should not automatically be attributed to the semaglutide issue. Stock Titan
Sources: Dr. Reddy's October 23 financial disclosures · Reuters — October 23 earnings report
Why it matters strategically
The results illustrate the interaction between commercial competition and manufacturing reliability.
Generic pharmaceutical businesses depend on competitive pricing, regulatory compliance, manufacturing efficiency, and reliable product availability.
These mechanisms can reinforce one another.
When prices decline, maintaining profitability requires stronger operational efficiency.
However, quality-related disruptions can increase costs through inventory losses, recalls, remediation, and interrupted product supply.
A manufacturer experiencing both price erosion and production problems may therefore face financial pressure greater than either issue would produce independently.
